header
Image from OpenLibrary

Impact of toll-like receptor 9 gene polymorphism (1237 t / c) on response to therapy in chronic hepatitis C Egyptian patients / Ghada Emam Abdelaziz ; Supervised Doha Abdelhamid Mokhtar , Rania Ahmed Ahmed Zayed , Dalia Abdelhamid Omran

By: Contributor(s): Material type: TextTextLanguage: English Publication details: Cairo : Ghada Emam Abdelaziz , 2016Description: 122 P. : charts , facsimiles ; 25cmOther title:
  • على الاستجابه للعلاج في المرضى المصريين المصابين بالالتهاب الكبدي الوبائي سي(T/C 1237) أثر التعدد الشكلى لجين مستقبل شبيه التول 9 [Added title page title]
Subject(s): Available additional physical forms:
  • Issued also as CD
Dissertation note: Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology Summary: Background and aim: Hepatitis C virus (HCV) infection leads to development of liver inflammation, causing morbidity and mortality. Multiple factors influence HCV progression, including genetic factors. Toll-like receptor 9 (TLR9) plays a key role in innate immunity and mutations in the genes encoding this receptor have been associated with progression of liver damage. Our aim is to detect TLR9 1237 T/C (rs5743836) single nucleotide polymorphisms (SNP) in chronic hepatitis C Egyptian patients to determine its association with susceptibility to infection, progression of fibrosis and response to treatment with interferon plus ribavirin. Results: genotype and allelic frequencies of TLR9 1237T/C SNP were not significantly different between studied HCV-positive patients and controls (P=0.373 and 0.405, respectively). TLR9 1237T/C SNP was not associated to treatment response, either ETR or SVR [OR (95% CI) of 0.834 (0.263{u2013}2.643) and 0.698 (0.253{u2013}1.928), respectively) and was not related to advanced stage of fibrosis (P= 0.183). Baseline AFP level was significantly higher in patients with advanced hepatic fibrosis (P= 0.000). Conclusion: TLR9 1237T/C (rs5743836) SNP is not associated to susceptibility to HCV infection, progression of fibrosis or response to combined treatment with Peg-INF plus ribavirin in HCV infected Egyptian patients.
Tags from this library: No tags from this library for this title. Log in to add tags.
Star ratings
    Average rating: 0.0 (0 votes)
Holdings
Item type Current library Home library Call number Copy number Status Date due Barcode
Thesis Thesis قاعة الرسائل الجامعية - الدور الاول المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.07.M.Sc.2016.Gh.I (Browse shelf(Opens below)) Not for loan 01010110070430000
CD - Rom CD - Rom مخـــزن الرســائل الجـــامعية - البدروم المكتبة المركزبة الجديدة - جامعة القاهرة Cai01.11.07.M.Sc.2016.Gh.I (Browse shelf(Opens below)) 70430.CD Not for loan 01020110070430000

Thesis (M.Sc.) - Cairo University - Faculty of Medicine - Department of Clinical and Chemical Pathology

Background and aim: Hepatitis C virus (HCV) infection leads to development of liver inflammation, causing morbidity and mortality. Multiple factors influence HCV progression, including genetic factors. Toll-like receptor 9 (TLR9) plays a key role in innate immunity and mutations in the genes encoding this receptor have been associated with progression of liver damage. Our aim is to detect TLR9 1237 T/C (rs5743836) single nucleotide polymorphisms (SNP) in chronic hepatitis C Egyptian patients to determine its association with susceptibility to infection, progression of fibrosis and response to treatment with interferon plus ribavirin. Results: genotype and allelic frequencies of TLR9 1237T/C SNP were not significantly different between studied HCV-positive patients and controls (P=0.373 and 0.405, respectively). TLR9 1237T/C SNP was not associated to treatment response, either ETR or SVR [OR (95% CI) of 0.834 (0.263{u2013}2.643) and 0.698 (0.253{u2013}1.928), respectively) and was not related to advanced stage of fibrosis (P= 0.183). Baseline AFP level was significantly higher in patients with advanced hepatic fibrosis (P= 0.000). Conclusion: TLR9 1237T/C (rs5743836) SNP is not associated to susceptibility to HCV infection, progression of fibrosis or response to combined treatment with Peg-INF plus ribavirin in HCV infected Egyptian patients.

Issued also as CD

There are no comments on this title.

to post a comment.